Industry Supported Sessions

Hall A
Tuesday, 6 May 2014
13.00 - 14.30	ASTRA ZENECA VACCINATING CHILDREN AGAINST INFLUENZA – UPDATE ON RECENT CHANGES IN EUROPE
15.00 - 16.30	GSK PUBLIC HEALTH STRATEGIES TO PREVENT BACTERIAL DISEASES IN CHILDHOOD
Wednesday, 7 May 2014
08.45 - 10.15	SANOFI PASTEUR MSD IMPROVING IMPLEMENTATION OF VACCINATION PROGRAMS
10.45 - 12.15	ABBVIE THE ONGOING GLOBAL CHALLENGE OF RSV INFECTION: EMERGING INTERVENTIONS AGAINST RSV
13.00 - 14.30	GSK *CERVARIX® 2-DOSE SCHEDULE: A NEW CHAPTER IN CERVICAL CANCER PREVENTION PROSPECTS OF A REDUCED SCHEDULE IN HPV VACCINATION**
15.00 - 16.30	NOVARTIS VACCINES TRANSFORMING THE LANDSCAPE OF MENINGOCOCCAL DISEASE PREVENTION
16.50 - 18.20	PFIZER PNEUMOCOCCAL VACCINATION: WHERE WE ARE AND WHERE WE ARE GOING

TUESDAY, MAY 6, 2014

VACCINATING CHILDREN AGAINST INFLUENZA – UPDATE ON RECENT CHANGES IN EUROPE

13:00 - 14:30

Chairperson: R. Belshe, USA

13:00–13:10 WELCOME AND INTRODUCTION
R. Belshe, USA, Chair

13:10–13:30 PAEDIATRIC INFLUENZA IMMUNISATION POLICY – THE NORDIC PERSPECTIVE
T. Kilpi, Finland

13:30–13:50 EFFECTIVENESS DATA AND POLICY UPDATE FROM GERMANY
M. Rose, Germany

13:50–14:15        THE 2013/14 UK (SCOTLAND) CHILDHOOD VACCINATION PROGRAMME – HOW
                             DID IT GO?
                             J. McMenamin, UK

14:15–14:30 QUESTIONS AND PANEL
Discussion led by R. Belshe, Chair

*************************************************************************

PUBLIC HEALTH STRATEGIES TO PREVENT BACTERIAL DISEASES IN CHILDHOOD

15:00-16:30

15:00 – 15:10 WELCOME AND INTRODUCTION
M. Slack, UK

15:10 – 15:30 STRATEGIES TO HELP PROTECT AGAINST MENINGOCOCCAL DISEASES
V. Papaevangelou, Greece

15:30 – 15:50 LESSONS LEARNT FROM PNEUMOCOCCAL VACCINATION PROGRAMMES
A. Palmu, Finland

15:50 – 16:10 PERTUSSIS: WHY DO WE NEED A LIFE-LONG STRATEGY?
C. Wirsing von Koenig, Germany

16:10 – 16:20 CONCLUDING REMARKS
M.Slack, UK

16:20 – 16:30 Q&A

WEDNESDAY, MAY 7, 2014

IMPROVING IMPLEMENTATION OF VACCINATION PROGRAMS

8:45 - 10:15

Chair: Prof. Ulrich Heininger

ROUTINE PAEDIATRIC VACCINATION IN EUROPE. SUCCESS AND CHALLENGES
U. Heininger

A NEW HEXAVALENT VACCINE UP TO CURRENT TIMES' EXPECTATIONS
F. Martinon-Torres

INTRODUCTION OF MMR/V VACCINES IN EU CHILDHOOD VACCINATION PROGRAMS
C. Giaquinto

HPV VACCINATION IN PRE-TEENS AND TEENS: INFORMATION, CHECK-UP AND CATCH-UP
C. Weil-Olivier

*************************************************************************

THE ONGOING GLOBAL CHALLENGE OF RSV INFECTION: EMERGING INTERVENTIONS AGAINST RSV

10:45– 12:15

10:45-10:50   WELCOME AND INTRODUCTION
                      Eleanor Molloy
10:50-11:15   NOVEL INSIGHTS IN RSV PATHOGENESIS, PREVENTION AND TREATMENT
                      Louis Bont
11:15-11:40   THE DEVELOPMENT OF THE PRETERM NEONATAL IMMUNE SYSTEM AND NEW
                      EVIDENCE ON THE ROLE OF VITAMIN D
                      Eleanor Molloy
11:40-12:05   ADVANCES IN RSV VACCINE DEVELOPMENT
                      Barnie Graham
12:05-12:15   Q&A

*************************************************************************

CERVARIX® 2-DOSE SCHEDULE*: A NEW CHAPTER IN CERVICAL CANCER PREVENTION

PROSPECTS OF A REDUCED SCHEDULE IN HPV VACCINATION

13.00 - 14.30

Moderator:
Mark Porter UK

Participants:
M. Van Ranst Belgium
C. Dannecker Germany
T. Schwarz Germany
C. Weil-Olivier, France

13:00–13:05 HPV AND CERVICAL CANCER – VIDEO

13:05–13:10 WELCOME AND INTRODUCTION

13:10–14:15 SHORT PRESENTATIONS AND ROUNDTABLE DISCUSSION ON FOLLOWING
TOPICS:

Incidence of cervical cancer
Prevention of cervical cancer through screening and vaccination
HPV vaccination compliance and coverage
Cervical cancer and its treatments
Introduction of Cervarix® 2-dose vaccination schedule* and results of clinical trials
Immunise today to protect later: the role of paediatricians in vaccination of young adolescent girls

14:15–14:25 Q&A

14:25–14:30 CONCLUSIONS

* Cervarix® 2-dose vaccination schedule is registered for 9-14 years old girls

*************************************************************************